Телфаст

Quick links to important sections

Телфаст

Selected form

Treatment option: Rhinitis, Hay Fever

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Телфаст

Quick Facts: Телфаст (Fexofenadine)

Property Description
Active ingredient Fexofenadine hydrochloride
Form Film-coated tablet, capsule, oral suspension, ODT
Pharmacological class Second-generation antihistamine
General purpose Relief from histamine-related physiological responses
Origin Synthetic (carboxylic acid metabolite)

What is Телфаст: Composition and Classification

Телфаст is a proprietary brand name for a medicine whose active ingredient is Fexofenadine hydrochloride. This medicinal entity is a synthetic, single-ingredient compound derived from the modification of terfenadine and is categorized as a Histamine H1 Antagonist. Fexofenadine is specifically classified as a second-generation antihistamine and a highly selective peripheral H1 blocker, distinguishing it from earlier generations of antihistamines. This medicine is recognized for its role in modulating the physiological effects arising from histamine release.

The Mechanism of Selective H1 Antagonism

The fundamental purpose of Fexofenadine is to provide relief by interrupting the physiological pathway of the allergic response through selective histamine blockade. The drug functions by competitively binding to and stabilizing the inactive form of the H1 receptors, thereby preventing the binding of the inflammatory chemical histamine released during allergic reactions. Fexofenadine is characterized by its non-sedating action and its minimal crossing of the blood-brain barrier compared to first-generation agents. This pharmacological profile allows for the management of the systemic effects of histamine with a reduced impact on the central nervous system.

Available Pharmaceutical Forms and Patient Focus

Fexofenadine is manufactured exclusively as a single-ingredient product intended for the oral route of administration. The Телфаст brand offers a range of dosage forms, including the standard film-coated tablet and capsule. Additionally, the availability of the oral suspension (liquid medicine) and an orally disintegrating tablet (ODT) ensures the product is positioned to serve a broad patient group, specifically accommodating adolescents and children who may require non-solid formats. This focus on diverse oral forms ensures that all presentations consistently deliver the active ingredient, Fexofenadine, for systemic absorption.

Regulatory References

  1. Histamine H1 Antagonist (MedlinePlus, NIH)

What side effects are possible with Телфаст?

Possible Side Effects and Safety Information

The safety profile for Fexofenadine (Телфаст) is formally organized into categories based on frequency and affected body systems, as documented in regulatory sources such as the EMA and FDA. Side effects are classified into specific System-Organ Classes (SOCs) for reporting consistency.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized by how often they are expected to occur based on clinical trials and post-marketing data:

  • Common (may affect up to 1 in 10 people): Headache, Drowsiness (Somnolence), Dizziness, and Nausea.
  • Uncommon (may affect up to 1 in 100 people): Fatigue and Insomnia.
  • Frequency Not Known (reported in post-marketing experience; rate cannot be estimated): Effects such as Tachycardia, Palpitations, Nervousness, Sleep Disorders (including Paroniria), and Diarrhoea have been documented.

Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but clinically significant Serious Hypersensitivity Reactions under the Immune System Disorders SOC. These documented events include Angioedema (swelling of deeper tissues), Chest tightness, Dyspnea (difficulty breathing), Flushing, and Systemic Anaphylaxis.

A fundamental safety restriction is the contraindication for individuals with a known hypersensitivity to the active substance, fexofenadine, or to any excipients in the preparation. Regarding specific populations, regulatory documents state that consideration for dosage modification may be necessary for patients with documented renal impairment, but generally no specific adjustment is required for older adults or those with hepatic impairment.

Overdose and Emergency Response

Documented Overdose Manifestations

Overdose of Телфаст (Fexofenadine) may lead to an exaggeration of known effects, as described in official prescribing information. Documented clinical manifestations can include drowsiness (somnolence), dizziness, and dry mouth. Other signs reported in the clinical context of overdose include headache, agitation, and tachycardia (rapid heart rate). In cases of large ingestion, there is a documented potential for serious cardiovascular effects, including QT interval prolongation and arrhythmias, which necessitate medical observation.

Emergency Actions and Urgent Help

Regulatory authorities mandate that in any suspected case of overdose, individuals must seek immediate medical attention. This explicitly requires contacting a Poison Control Center right away. Urgent medical services must be called immediately if severe or life-threatening manifestations are present, such as collapse, seizure, trouble breathing, or unconsciousness. Acute ingestion of more than three times the maximum daily dose in children also serves as a specific trigger for mandatory medical assessment.

Official Management Protocol

The primary management required for Fexofenadine overdose is symptomatic and supportive treatment. Official documentation confirms that no specific antidote is known for this medication. Procedures such as the use of activated charcoal may be considered in cases of massive ingestion. It is explicitly noted that hemodialysis is not effective for removing Fexofenadine from the body. Monitoring, including cardiac observation, may be necessary with large overdoses.

Therapeutic Uses of Телфаст

What Телфаст Treats: Main Uses and Benefits

Телфаст is commonly used across domains where additional symptomatic support is needed in situations involving certain distressing allergic symptoms. It is relevant in contexts involving systemic or localized discomfort and may assist with managing symptom clusters that create noticeable functional strain. The medication is considered relevant for conditions characterized by periods of heightened symptoms, including seasonal allergic rhinitis, perennial rhinitis, chronic idiopathic urticaria (hives), and acute manifestations like allergic conjunctivitis.

Applied in clinical settings that involve acute or unstable symptom patterns, it provides support that may help ease the overall symptom burden. Телфаст is generally considered relevant for managing symptoms that interfere with daily comfort. This supportive relief is helpful in situations requiring additional symptomatic assistance when symptoms become temporarily overwhelming or create noticeable functional strain.


Quick Fact: Relief for Disruptive Allergic Symptoms

Symptom Category Relief Focus Scenario of Use
Respiratory Sneezing, runny nose, itchy throat Seasonal or perennial allergen exposure
Cutaneous Pruritus (itching), hives (wheals) Chronic urticaria or insect bite reactions
Ocular Redness, itching, watering eyes Allergic conjunctivitis episodes

Regulatory References

  1. NIH MedlinePlus overview of Fexofenadine

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Телфаст

This eligibility profile is based strictly on formal statements from government regulatory documents, outlining which populations are approved for use, restricted, or contraindicated.


Populations for Whom Use is Contraindicated

  • Hypersensitivity: The medicine is contraindicated in patients with a known allergy or hypersensitivity to the active substance, fexofenadine, or to any excipients in the formulation.

Age-Related Eligibility

  • Adults and Adolescents (12 years and older): Use is approved for this group for both major indications.
  • Children (6 to 11 years): Approved for use, typically utilizing specific lower-strength tablets or oral suspension.
  • Children Under 6 Years (Tablets): Standard tablet formulations are not recommended. The safety and efficacy for the drug's use are not established in infants under 6 months of age.

Populations Requiring Conditional Use

  • Renal Impairment: Patients with impaired kidney function are a special risk group for whom regulators advise caution. Official labeling may recommend a lower starting dose for these patients.
  • Cardiovascular Conditions: Caution is advised for patients with a history of, or ongoing, cardiovascular disease.
  • Pregnancy and Lactation: Use is not recommended in women who are pregnant or breastfeeding unless deemed necessary due to insufficient human safety data.

Connection to the overall eligibility profile

Regulatory documents define eligibility for Fexofenadine by establishing an absolute prohibition based on hypersensitivity and imposing conditional restrictions on specific populations defined by age, renal function, and physiological state (pregnancy/lactation). This structure ensures the medicine is used only within the boundaries documented by official health authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for fexofenadine establishes specific constraints concerning co-administration with certain substances due to documented pharmacokinetic interactions that modify the drug's systemic exposure.

Drug–Drug and Drug–Substance Interactions

Co-administration with Ketoconazole or Erythromycin results in a pharmacokinetic interaction where the plasma concentration of fexofenadine is increased. Regulatory bodies attribute this increased systemic exposure to the P-glycoprotein (P-gp) inhibitory potential of both Ketoconazole and Erythromycin. No clinically relevant CYP-mediated metabolic interactions or pharmacodynamic interactions are documented in major regulatory labels.

Administration Constraints and Timing Rules

Interacting Product Category Regulatory Constraint Official Mechanism/Outcome
Aluminum/Magnesium-containing Antacids Must be separated by approximately 2 hours from fexofenadine administration. Prevents a reduction in fexofenadine absorption and exposure.
Specific Fruit Juices (e.g., Grapefruit, Orange, Apple) Avoid co-ingestion. Reduces the oral bioavailability and systemic exposure of fexofenadine.
Alcohol No clinically significant interaction is formally documented. N/A

The drug's interaction profile is primarily defined by these P-gp transport and absorption-related changes, requiring mandatory administrative steps to maintain appropriate fexofenadine exposure. No combinations are formally classified as contraindicated due to interaction risk.

Mechanism of Action

How Telfast Works at the Molecular Level


Selective Histamine H1 Receptor Blockade

Telfast (fexofenadine) acts within domains involving receptor-mediated signaling by binding to the peripheral histamine H1 receptors . This action competitively prevents the natural signaling molecule, histamine, from binding and activating the receptor, which is the key early molecular step that initiates the downstream cellular and tissue effects.


Modulating the Inflammatory Signaling Cascade

This mechanism suppresses signaling sequences that typically proceed to downstream cellular and tissue effects by stabilizing the H1 receptor in an inactive state. By inhibiting the histamine signaling pathway, the drug reduces the functional consequence of elevated mediator activity and contributes to a modulated receptor signaling state within targeted pathways. This results in subsequent physiological changes consistent with receptor antagonism.

Dosage and Administration Information

How Телфаст is Used: Official Dosing and Administration

Телфаст (Fexofenadine) is administered strictly via the oral route using various official forms, including film-coated tablets (e.g., 60 mg, 180 mg), oral suspension, and orally disintegrating tablets (ODT). Adherence to the prescribed frequency and specific intake conditions is crucial for proper use.


Official Dosing and Frequency

Official dosing is based on patient age and kidney function, maintaining a once daily (QD) or twice daily (BID) schedule.

Population (12 years and older) Standard Recommended Dose Frequency
Adults 180 mg OR 60 mg Once Daily (QD) OR Twice Daily (BID)
Renal Impairment 60 mg Once Daily (QD)

For children aged 6 to 11 years, the standard dose is typically 30 mg twice daily. Doses for infants and toddlers use the oral suspension form.


Administration Requirements

Key instructions govern how the medicine must be taken:

  • Liquid Avoidance: Do not take Fexofenadine with fruit juices (such as grapefruit, orange, or apple), as this may significantly reduce the amount of medicine absorbed by the body.
  • Antacids: The dose must be separated from aluminum- and magnesium-containing antacids by at least 2 hours to prevent reduced absorption.
  • ODT Form: Orally disintegrating tablets should be allowed to dissolve on the tongue and are generally recommended to be taken on an empty stomach. The standard film-coated tablets can be taken with water.

Following these administration guidelines ensures use of the medicine is consistent with the instructions specified in the official labeling.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Activity Profile

Preclinical research has investigated the drug's activity, which is classified as a second-generation antihistamine used to address allergy symptoms.


Efficacy Data

Clinical trials evaluated whether fexofenadine (the active substance in Телфаст) was associated with changes in the frequency and severity of symptoms related to seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). Key findings were primarily drawn from Phase 3 randomized, double-blind, placebo-controlled trials.

  • Seasonal Allergic Rhinitis: Studies examined the effect of fexofenadine on common symptoms such as sneezing, watery eyes, itchy nose, and palate. Trials reported that the severity of these symptoms in the group receiving the drug differed from the placebo group. The duration of relief was also a primary focus of these investigations.
  • Chronic Idiopathic Urticaria: Research explored the effects on symptoms including the number of wheals and the severity of itching. Findings suggested differences in these measured endpoints between the active treatment group and the placebo group over the study periods.

Safety and Tolerability

The safety profile was evaluated across all clinical trials. The most frequently reported adverse events (AEs) included headache, nausea, and mild rash. Serious adverse events were rare and were reported in a small percentage of participants in both the drug and placebo groups. Adverse events were generally reported to be of a low grade.


Participant Population

The participant population in these studies included adults and, in some trials, children with confirmed diagnoses of seasonal allergic rhinitis or chronic idiopathic urticaria, as determined by the enrolling specialists.

Key Studies & References

  1. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study
  2. Public Assessment Report Fexo 120 mg film-coated tablets (HPRA - Ireland)

Frequently Asked Questions (FAQ)

Common questions about Телфаст (FAQ)

Q: What is the general difference between Телфаст 120 mg and Телфаст 180 mg?

Official product information indicates that the 120 mg dose is typically used for the relief of symptoms associated with seasonal allergic rhinitis (hay fever). The higher 180 mg dose is often indicated for the treatment of symptoms associated with chronic idiopathic urticaria (hives). Information about the appropriate dose for an individual’s condition is provided by a healthcare professional.

Q: Is it necessary to take Телфаст before a meal, or can it be taken with food?

Regulatory documents state that the standard film-coated tablets are typically recommended to be taken before a meal. It is also advised that the orally disintegrating tablet (ODT) formulation is taken on an empty stomach. These guidelines are in place to help support the medicine's systemic exposure.

Q: Are there any documented side effects related to changes in mood or anxiety when taking Телфаст?

Post-marketing surveillance reports have included adverse events affecting the nervous system, such as nervousness and sleep disorders, including nightmares. These types of effects are noted in the official information but are reported with a frequency that is not known. Concerns about changes in mood or anxiety should be reviewed with a health professional.

Q: What evidence exists about the use of Телфаст for long-term skin itching (pruritus)?

Studies and official information indicate that fexofenadine is approved for treating the symptoms of chronic idiopathic urticaria (hives), which includes itching. The efficacy for long-term, non-specific itching alone is not an official approved indication for the medicine. Decisions regarding the use of the drug for persistent itching not due to urticaria should be made with a healthcare professional.

Q: Are there any known non-prescription medicines that should be avoided with Телфаст?

The official drug labeling explicitly warns about certain non-prescription items that may reduce drug absorption. Antacids containing aluminum and magnesium must be separated from fexofenadine administration by approximately two hours. These guidelines are in place to help maintain the drug’s intended systemic exposure.

Q: Does Телфаст have anticholinergic effects that can cause side effects like dry mouth?

Preclinical research cited in the official label suggests that fexofenadine does not exhibit anticholinergic effects (which typically cause dry mouth). However, despite this mechanism, side effects such as dry mouth have still been reported in post-marketing surveillance. This effect is not classified among the common side effects listed in clinical trials.

Q: What common strategies are described for coping with side effects like dry mouth or dizziness?

Patient information leaflets, which reflect regulatory guidance, describe simple, non-clinical strategies for managing some side effects. For instance, if you experience dizziness, it is advised to sit or lie down until the feeling passes and to get up slowly. Side effects that persist or are bothersome should be discussed with a healthcare professional.

Q: How quickly does Телфаст typically start to relieve symptoms after a dose?

Official product information indicates that the antihistaminic effect has been reported to begin within one hour of administration. Maximum concentrations of the drug in the body are typically reached in two to three hours. This suggests symptom relief may start relatively quickly after a dose.

Q: How long is a single dose of Телфаст generally expected to provide relief?

Clinical data and regulatory summaries demonstrate that the antihistaminic effect of a single dose of fexofenadine lasts for approximately 24 hours. This long duration of action supports the once-daily dosing schedules found in official recommendations.

Q: Is it safe to take Телфаст every day for an extended period, such as a full allergy season?

Fexofenadine is indicated for chronic conditions, such as chronic idiopathic urticaria (hives), which often require long-term administration. Official regulatory labeling does not specify a maximum duration for continuous use in approved patient populations. Discussions regarding long-term use should be guided by a health professional.

Q: Is it true that the effectiveness of Телфаст can wear off over time (develop a tolerance)?

Studies of antihistaminic effect have specifically examined whether the effectiveness of fexofenadine decreases over time. Official product information indicates that no evidence of tolerance development to the effects of fexofenadine has been found after 28 days of continuous dosing.

Q: Can Телфаст be taken at the same time as nasal steroid sprays for hay fever?

Official drug interaction documents primarily focus on systemic (body-wide) interactions and do not list specific interactions with topical nasal steroid sprays. Consultation with a healthcare professional is suggested prior to combining medications.

Q: What is the difference in components between Телфаст and the combination product Телфаст-D?

The standard product contains fexofenadine as a single active ingredient. Combination products (often designated with '-D') contain both fexofenadine (the antihistamine) and a decongestant component, typically pseudoephedrine. The addition of pseudoephedrine addresses nasal congestion, which fexofenadine alone does not target.

Q: What is the recommendation if a dose of Телфаст is forgotten?

Patient information leaflets advise that if a dose is forgotten, the patient should simply skip the missed dose and take the next scheduled dose at the regular time. It is important not to take a double dose to make up for the forgotten dose.

Q: Does Телфаст affect the reliability of hormonal birth control (contraception)?

Regulatory documents and drug interaction studies indicate there are no clinically significant drug interactions established between fexofenadine and the components of common hormonal contraceptives. Therefore, fexofenadine is not expected to affect the reliability of birth control.

Q: Is there any official information suggesting that Телфаст is gluten-free or lactose-free?

The composition of the tablets may vary by formulation and manufacturer. Official labeling (DailyMed) indicates that some tablet formulations contain inactive ingredients such as lactose monohydrate. Individuals with specific dietary concerns, such as lactose intolerance or gluten sensitivity, should consult the package leaflet for the exact formulation.

Q: Can Телфаст be taken with other types of over-the-counter allergy medications?

Co-administration with other types of antihistamine medications is generally advised against due to the potential for compounded effects, unless under the guidance of a healthcare professional. Combination formulations that include a decongestant are available if additional symptom relief is needed.

Q: What are the official guidelines regarding driving or operating machinery while taking Телфаст?

While fexofenadine is generally classified as non-sedating, official guidelines advise caution regarding driving or operating machinery. A small number of people may still experience side effects like mild drowsiness or dizziness, which could impair their ability to operate safely. Official guidance recommends that individuals assess their response before driving or operating machinery.

Q: Can Телфаст be taken for a common cold, or is it only for allergies?

The medicine is officially indicated for the relief of symptoms related to seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). The official Uses and Indications sections do not list the common cold as an approved use for this medicine.

Q: What side effects, if any, are common across different concentrations of Телфаст (e.g., 120mg vs 180mg)?

Clinical trial data and regulatory documents generally indicate that the adverse effect profile is similar across the different approved oral doses. No significant dose-related trends in the frequency of common side effects have been noted between standard concentrations, such as 120 mg and 180 mg.

How should Телфаст be stored and disposed of?

Storage and Disposal Requirements

Telfast (fexofenadine hydrochloride) must be stored under specific conditions to maintain product stability and safety, as documented in official labeling.

Constraint Category Official Regulatory Requirements
Storage Temperature Store tablets at controlled room temperature, typically 20 C to 25 C (68 F to 77 F) or below 30 C [1.1, 1.5].
Protection & Packaging Must be protected from excessive moisture and light. Keep the medicine in the original container, tightly closed, and do not use if the inner seal is compromised [1.2].
Child Safety The medicine must be kept out of the sight and reach of children [2.1].
Disposal Instructions Do not dispose of this medicine via wastewater or household waste [2.1]. Patients must ask a pharmacist for instructions on how to properly discard any unused or expired product [2.1].

These constraints define how the drug must be stored, handled, and ultimately disposed of according to regulatory standards, ensuring stability until the stated expiry date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Телфаст found in:

A-Z Index: